Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aviptadil Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Relief Announces Six-Month Stability Data on a New Formulation of RLF-100
    Relief Announces Six-Month Stability Data on a New Formulation of RLF-100

    07 Nov 2022

    // ACCESSWIRE

    https://www.accesswire.com/724162/Relief-Therapeutics-Announces-Six-Month-Stability-Data-on-a-New-Formulation-of-RLF-100-Aviptadil

    ACCESSWIRE
    07 Nov 2022
    Share Share
    Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)
    Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)

    03 Aug 2022

    // ACCESSWIRE

    https://www.accesswire.com/710682/Relief-Therapeutics-Announces-Promising-Initial-Stability-Data-on-a-New-Formulation-of-RLF-100R-Aviptadil

    ACCESSWIRE
    03 Aug 2022
    Share Share
    Déjà vu: FDA rejects NRx filing for emergency use in COVID-19
    Déjà vu: FDA rejects NRx filing for emergency use in COVID-19

    02 Jul 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/deja-vu-fda-rejects-nrx-filing-emergency-use-covid-19

    Nick Paul Taylor FIERCEBIOTECH
    02 Jul 2022
    Share Share
    NRx Pharma Provides Update on BTD Request for ZYESAMI
    NRx Pharma Provides Update on BTD Request for ZYESAMI

    10 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-provides-update-on-breakthrough-therapy-designation-btd-request-for-zyesami-aviptadil-301566128.html

    PRNEWSWIRE
    10 Jun 2022
    Share Share
    NRx tanks as peptide fails NIH trial in severe COVID-19 patients
    NRx tanks as peptide fails NIH trial in severe COVID-19 patients

    27 May 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/activ-nrx-tanks-peptide-fails-nih-trial-severe-covid-19-patients

    N.P. Taylor FIERCEBIOTECH
    27 May 2022
    Share Share
    NRx to halt analysis of Zyesami for critical Covid-19 due to futility
    NRx to halt analysis of Zyesami for critical Covid-19 due to futility

    27 May 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/nrx-zyesami-covid-futility/

    CLINICALTRIALSARENA
    27 May 2022
    Share Share